ImmunoGen

ImmunoGen presents data from IMGN779 study in acute myeloid leukemia

Monday, June 26, 2017

ImmunoGen, a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, presented data from the ongoing phase I study evaluating single agent IMGN779 in patients with relapsed or refractory adult acute myeloid leukemia (AML) whose tumors express CD33. The first-in-human data demonstrate the safety and tolerability of IMGN779 across seven dose levels, with no dose limiting toxicities (DLTs), as well as evidence of dose-dependent biological and anti-leukemia activity.

[Read More]

ImmunoGen doses first patient in phase III ovarian cancer study

Friday, January 27, 2017

ImmunoGen, a provider of antibody-drug conjugates (ADCs) for the treatment of cancer, has announced that the first patient has been dosed in FORWARD I, the company’s phase III clinical trial evaluating mirvetuximab soravtansine as a single-agent therapy for the treatment of platinum-resistant ovarian cancer. Mirvetuximab soravtansine is a first-in-class, folate receptor alpha (FRα)-targeting ADC.

[Read More]

ImmunoGen to cut workforce 17%

Tuesday, October 4, 2016

ImmunoGen, a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, has announced the completion of a strategic review of its operations. As a result of this initiative, the company will reduce its workforce by 17% and seek to partner its non-core B-cell lymphoma programs, creating a stronger organization focused on delivering innovative ADC therapies that meaningfully improve the lives of cancer patients.

[Read More]

TransCelerate Biopharma turns three

Monday, June 1, 2015

The name alone excites many in clinical research. It’s the first—or so far best promoted—consortium consisting only of high-level people from big biopharmaceutical companies, each vowing to be deeply “pre-competitive” with one another while trying to rework some of the redundant and wasteful practices endemic to clinical research.

[Read More]

Takeda, ImmunoGen partner

Monday, March 23, 2015

Takeda Pharmaceutical, a research-based global company headquartered in Osaka, Japan, has licensed exclusive rights to use ImmunoGen‘s ADC technology—including ImmunoGen’s new DNA-acting IGN payload agents—to develop and commercialize targeted anticancer therapeutics to up to two undisclosed targets.

[Read More]

ImmunoGen announces fifth new license agreement this year

Monday, November 11, 2013

ImmunoGen, a biotechnology company that develops targeted anticancer therapeutics, has announced Novartis has licensed the exclusive right to use the company’s antibody-drug conjugate (ADC) technology to develop anticancer therapeutics to an undisclosed target. This is the third license to be taken by Novartis—and the fifth to be taken by a major healthcare company—this year.

[Read More]